Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Japanese Subjects With Hematological Malignancies
NCT02265731Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in non-Hodgkin lymphoma (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Sep 2014; status: completed.
02
Drugs
venetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02265731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265731.